

Daniel J G Thirion

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3580299/publications.pdf>

Version: 2024-02-01

15
papers

170
citations

1163065

8
h-index

1125717

13
g-index

15
all docs

15
docs citations

15
times ranked

243
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutropenia in kidney and liver transplant recipients: Risk factors and outcomes. <i>Clinical Transplantation</i> , 2017, 31, e13058.	1.6	28
2	Potential of Warfarin's Hypoprothrombinemic Effect with Miconazole Vaginal Suppositories. <i>Pharmacotherapy</i> , 2000, 20, 98-99.	2.6	27
3	Impact of an Infection Control and Antimicrobial Stewardship Program on Solid Organ Transplantation and Hepatobiliary Surgical Site Infections. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 1468-1474.	1.8	23
4	Telithromycin-Induced Digoxin Toxicity and Electrocardiographic Changes. <i>Pharmacotherapy</i> , 2006, 26, 872-876.	2.6	18
5	The 2017 global point prevalence survey of antimicrobial consumption and resistance in Canadian hospitals. <i>Antimicrobial Resistance and Infection Control</i> , 2020, 9, 104.	4.1	12
6	Antimicrobial use among adult inpatients at hospital sites within the Canadian Nosocomial Infection Surveillance Program: 2009 to 2016. <i>Antimicrobial Resistance and Infection Control</i> , 2020, 9, 32.	4.1	12
7	Influence of a 5-year serial infection control and antibiotic stewardship intervention on cardiac surgical site infections. <i>American Journal of Infection Control</i> , 2016, 44, 977-982.	2.3	11
8	Pharmacokinetic equations versus Bayesian guided vancomycin monitoring: Pharmacokinetic model and model-informed precision dosing trial simulations. <i>Clinical and Translational Science</i> , 2022, , .	3.1	10
9	The 2018 Global Point Prevalence Survey of antimicrobial consumption and resistance in 47 Canadian hospitals: a cross-sectional survey. <i>CMAJ Open</i> , 2021, 9, E1242-E1251.	2.4	8
10	Amikacin nomogram for treatment of adult cystic fibrosis exacerbations based on an external evaluation of a population pharmacokinetic model. <i>Pediatric Pulmonology</i> , 2020, 55, 1154-1160.	2.0	6
11	Antimicrobial utilization data: Does point prevalence data correlate with defined daily doses?. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 920-921.	1.8	5
12	Role of high-risk antibiotic use in incidence of health-care-associated <i>Clostridioides difficile</i> infection in Quebec, Canada: a population-level ecological study. <i>Lancet Microbe</i> , The, 2021, 2, e182-e190.	7.3	5
13	The Art of Assessing Metronidazole Toxicity. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1184-1184.	4.4	2
14	Antimicrobial use in Canadian acute-care hospitals: Findings from three national point-prevalence surveys between 2002 and 2017. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 1558-1564.	1.8	2
15	What is the recommended amikacin dosing for cystic fibrosis patients with acute pulmonary exacerbations?. <i>Pediatric Pulmonology</i> , 2019, 54, 1652-1653.	2.0	1